Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Trianni
San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Trianni’s transgenic mouse platforms enable highly efficient discovery of fully human monoclonal antibodies. Multiple large pharma companies have benchmarked the Trianni Mouse as comparable or superior to competing technologies, and the platform is actively licensed and validated both internally and externally. The platform supports the rapid isolation of high-quality therapeutic monoclonal antibodies, including bispecifics and single-domain antibodies[1][3][4][5].
- Therapeutic areas
- Other
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyHumanized single-chain antibody fragmentSingle-domain antibody
- Industry
- Drug Discovery Services
02
Partnerships
Beyond the preview
Go deeper on Trianni.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trianni.